Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | TSPO | P30536 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71453 | 0.89 | PTGER4 (0.68) | PTGER4PTGER3PTGER1PTGER2FFAR1 | |
| SCHEMBL246473 | 0.85 | MEN1 (0.59) | PTGER4PTGER3PTGER1PTGER2FFAR1 | |
| SCHEMBL29444401 | 0.85 | MEN1 (0.59) | PTGER4PTGER3PTGER1PTGER2FFAR1 | |
| SCHEMBL27918771 | 0.84 | MPO (0.50) | PTGER4PTGER3PTGER1PTGER2MEN1 | |
| SCHEMBL538984 | 0.81 | CXCL8 (0.57) | MEN1ALDH1A1KMT2A | |
| Acetic Acid SCHEMBL29114584 | 0.80 | MEN1 (0.54) | PTGER4PTGER3PTGER1PTGER2FFAR1 | |
| SCHEMBL1261128 | 0.79 | PTGER4 (0.77) | PTGER4PTGER3PTGER1PTGER2FFAR1 | |
| SCHEMBL31212507 | 0.79 | PTGER4 (0.77) | PTGER4PTGER3PTGER1PTGER2FFAR1 | |
| SCHEMBL4610927 | 0.79 | PTGER4 (0.66) | PTGER4PTGER3PTGER1PTGER2FFAR1 | |
| SCHEMBL2208826 | 0.78 | PTGER4 (0.65) | PTGER4PTGER3PTGER1PTGER2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0862549-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE CARBOXYLIC ACIDS | UNION CARBIDE CHEM PLASTIC (US) | 2000-05-31 | — | — | EP | claimed |
| US-5998660-A | BY-PRODUCT INHIBITION | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1999-12-07 | — | — | US | claimed |
| EP-0862549-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE CARBOXYLIC ACIDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-09-09 | — | — | EP | claimed |
| US-5739385-A | OXIDIZING AN OPTICALLY ACTIVE ALDEHYDE WITH A PERACID IN THE PRESENCE OF AN AMINE AND/OR AMINE N-OXIDE CATALYST | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-04-14 | — | — | US | claimed |
| US-5739352-A | Process for preparing carboxylic acids | UNITED CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-04-14 | — | — | US | claimed |
| WO-1997014669-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE CARBOXYLIC ACIDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-04-24 | — | — | WO | claimed |
| US-20160326085-A1 | 2-ARYL-ZINC-PROPIONATE CATALYST AND PREPARATION METHOD AND USE THEREOF | FUDAN UNIVERSITY (CN) | 2016-11-10 | — | — | US | disclosed |
| US-5998660-A | BY-PRODUCT INHIBITION | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0601191-B1 | NOVEL TETRACYCLIC COMPOUND | KYOWA HAKKO KOGYO KK (JP) | 1998-07-22 | — | — | EP | disclosed |
| US-5739352-A | Process for preparing carboxylic acids | UNITED CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-04-14 | — | — | US | disclosed |
| US-5371225-A | Immunosuppressants | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| EP-0601191-A1 | NOVEL TETRACYCLIC COMPOUND | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0240863-B1 | CONTINUOUS PROCESS FOR THE ALKYLATION OF CH-ACID COMPOUNDS WITH ALKYL CARBONATES IN GAS-LIQUID PHASE TRANSFER CATALYSIS CONDITIONS | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1991-10-09 | — | — | EP | disclosed |
| US-4894471-A | Continuous process for the alkylation of CH-acid compounds with alkyl carbonates in gas-liquid phase transfer catalysis-conditions | CONSIGLIO NAZIONALE DELLE RICHERCHE (IT) | 1990-01-16 | — | — | US | disclosed |
| EP-0240863-A1 | Continuous process for the alkylation of CH-acid compounds with alkyl carbonates in gas-liquid phase transfer catalysis conditions | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1987-10-14 | — | — | EP | disclosed |
| US-4542233-A | Process for preparing biaryl compounds via coupling of an arylamine with an arene | BIASCHIM S.P.A. (IT) | 1985-09-17 | — | — | US | disclosed |
| US-4021478-A | Preparation of carboxylic acids from glycidonitriles with ionic lewis acids | THE UPJOHN COMPANY (US) | 1977-05-03 | — | — | US | disclosed |
| US-3994964-A | Processes for the production of carboxylic acids from glycidonitriles | THE UPJOHN COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3975431-A | Preparing carboxylic acids from glycidonitriles through enol acylates | THE UPJOHN COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326085-A1 | 2-ARYL-ZINC-PROPIONATE CATALYST AND PREPARATION METHOD AND USE THEREOF | CYP2F1, CYP4F2, CYP2A6 | PTGER4 155/4885PTGER3 121/4885PTGER1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.